Research
-
Prescription Opioid Use in General and Pediatric Emergency Departments
Children, adolescents, and young adults treated in pediatric emergency departments are much less likely to be prescribed opioids compared to patients of similar age and ailment treated at general EDs.
Categorized in -
Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments
Should Congress reauthorize funding for the Patient-Centered Outcomes Research Institute (PCORI)? Professor William Padula writes the PCORI can generate research relevant for shifting to value-based healthcare.
Categorized in -
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?
This study provides the first evidence to our knowledge that near-universal access to Medicare at age 65 is associated with improvements in population-level cancer mortality, and provides new evidence on the differences in the impact of health insurance by gender.
Categorized in -
Analysis of State-Level Drug Pricing Transparency Laws in the United States
In this letter published in JAMA Network Open, Neeraj Sood and Martha Ryan analyze recently enacted prescription drug pricing laws with a transparency component to determine which were informative and disclosed transaction prices.
Categorized in -
State Drug Pricing Transparency Laws: Numerous Efforts, Most Fall Short
166 recently enacted prescription drug pricing laws were analyzed to identify those that contained price transparency measures. Of these, 35 bills in 22 states include a transparency component, but only 7 were deemed to be informative.
Categorized in -
Data Visualization: State Drug Transparency Laws
States are increasingly enacting price transparency laws designed to provide regulators or the public with more information about how entities in the drug distribution system set prices. The data visualization summarizes the 35 drug pricing transparency bills enacted in states between 2015 and 2018.
Categorized in -
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017
High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
Categorized in -
County-Level Unemployment Rates and Service Intensity in Primary Care Physician Offices for Medicare Patients
Patients change their behavior and the way they interact with the healthcare system in the face of an economic recession, and findings also suggest primary care providers changed their service intensity as a result of the recession.
-
Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries
The burden of Alzheimer’s disease and other dementias is rapidly growing. Researchers found vast majority of dementia patients don’t receive specialty diagnosis and care.
-
Contribution Of Care Source To Cancer Treatment Cost Variation In The US Military Health System
Seth Seabury and colleagues examined how care received from military treatment facilities or purchased care in civilian facilities contributed to cancer treatment costs for patients.